ImmunityBio Inc. (IBRX)
IBRX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$9.80
-3.16% on the day
Market cap
$10.4B
Large cap
Revenue · 2025
$113.3M
+668.3% on 2024
Net income · 2025
-$351.5M
-310.3% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | IBRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001326110 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $113.3M |
| Net income | -$351.5M |
| Operating income | -$256.0M |
| Net margin | -310.3% |
| Operating margin | -226.0% |
| Revenue growth | +668.3% |
| Cash | $88.3M |
| Total assets | $501.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 91.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-29 |
| Latest annual report | 10-K | 2026-02-23 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-08-04 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 553 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.5% |
| 1 month | +21.6% |
| 3 months | +32.9% |
| Year to date | +400.0% |
| 1 year | +299.2% |
| From 52-week high | -14.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PCVX | Vaxcyte Inc. | $66.80 | -5.45% | $10.5B |
| TWST | Twist Bioscience Corporation | $151.33 | -0.35% | $10.0B |
| KRYS | Krystal Biotech Inc. | $321.16 | -3.29% | $9.5B |
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
| QGEN | Qiagen N.V. Common Shares | $45.44 | +0.29% | $9.4B |
| KYMR | Kymera Therapeutics Inc. | $106.68 | -4.82% | $8.9B |
| HALO | Halozyme Therapeutics Inc. | $109.62 | -1.31% | $12.4B |
| RGEN | Repligen Corporation | $175.42 | +1.69% | $8.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier